Bone Therapeutics Completes Recruitment in ALLOB Phase IIA Spinal Fusion Study

Bone Therapeutics completed recruitment for its ALLOB® allogeneic cell therapy Phase IIA spinal fusion study. The company will extend the trial to assess early onset of bone formation and fusion.

Of 18 patients enrolled, 16 were eligible and 15 received treatment, with no treatment-related safety concerns reported.

The extension is designed...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us